H. Watz (Großhansdorf, Germany), D. Halpin (Devon, United Kingdom), G. Caramori (Messina (ME), Italy), A. Turner (Birmingham (West Midlands), United Kingdom)
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
k. ohtsuka (Kawasaki, Japan), C. Maeda (Kawasaki, Japan), Y. Shinka (Kawasaki, Japan), T. Takahashi (Kawasaki, Japan), N. Harada (Kawasaki, Japan), M. Yagihashi (Kawasaki, Japan), J. Fujitake (Kawasaki, Japan), T. Udagawa (Kawasaki, Japan), N. Miyao (Kawasaki, Japan)
|  |
Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial
F. Maltais (Quebec, Canada), C. Vogelmeier (Marburg, Germany), I. Boucot (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), E. Kerwin (Medford, OR, United States of America), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom)
|  |
Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial
P. Jones (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), F. Maltais ( Québec City, QC, Canada), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs ( Uxbridge, Middlesex, United Kingdom), I. Boucot (Brentford, Middlesex, United Kingdom), T. Keeley (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America)
| |
Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial
C. Vogelmeier (Marburg, Germany), I. Naya (Brentford, Middlesex, United Kingdom), L. Tombs (Stockley Park West, Uxbridge, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America), L. Bjermer (Lund, Sweden), I. Boucot (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), F. Maltais (Quebec, Canada)
| |
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
S. Salvi (Pune, India), A. Kumar (Kanpur, India), S. Agrawal (Pune, India), A. Leuva (Vadodara, India), V. Shukla (Lucknow, India), S. Deshpande (Ulhasnagar, India), S. Balamurugan (Chennai, India), A. Singh (Jaipur, India), S. Tikkiwal (Jaipur, India), S. Gupta (Lucknow, India), S. Sawant (Mumbai, India), A. Vaidya (Mumbai, India), J. Gogtay (Mumbai, India)
| |
Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial
E. Kerwin (Medford, OR, United States of America), C. Vogelmeier (Marburg, Germany), F. Maltais (Quebec, Canada), I. Boucot (Brentford, Middlesex, United Kingdom), L. Tombs (Uxbridge, Middlesex, United Kingdom), I. Naya (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), T. Keeley (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden)
| |
Clinical Assessment of Glycopyrronium in COPD phenotypes and ACOS: Prospective, case control, observational study
K. Korukonda (Mumbai, India), P. Prabhudesai (Mumbai, India), B. Parthasarathi (Kolkata, India), B. Singh (Lucknow, India), S. Katiyar (Kanpur, India)
| |
Effects of different classes of bronchodilators on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease>
V. Calancea (Chisinau, Republic of Moldova), E. Terna (Chisinau, Republic of Moldova), T. Dumitras (Chisinau, Republic of Moldova), N. Ghicavii (Chisinau, Republic of Moldova), A. Popescu (Chisinau, Republic of Moldova), D. Baba (Chisinau, Republic of Moldova), S. Matcovschi (Chisinau, Republic of Moldova)
| |
COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol
P. Bhattacharyya (Kolkata, India), S. Dasgupta (Kolkata, India), S. Sengupta (Kolkata, India), D. Saha (kolkata, India), D. Dey (kolkata, India), M. Pal (kolkata, India)
| |
Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)
K. Rabe (Kiel, Germany), L. Fabbri (Gothenburg, Sweden), F. Martinez (New York, United States of America), G. Ferguson (Farmington Hills, United States of America), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), C. Reisner (Morristown, United States of America), P. Dorinsky (Durham, United States of America)
| |
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time
D. Lipson (Collegeville and Philadelphia, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, MI, United States of America), C. Jones (Research Triangle Park, NC, United States of America), S. Kilbride (Stockley Park, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, NY, United States of America), H. Quasny (Research Triangle Park, NC, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, MD, United States of America)
| |
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints
M. Han (Ann Arbour, MI, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), C. Jones (Research Triangle Park, NC, United States of America), S. Kilbride (Stockley Park, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, NY, United States of America), H. Quasny (Research Triangle Park, NC, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, MD, United States of America), D. Lipson (Collegeville and Philadelphia, United States of America)
| |
Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD
M. Polyzoi (Stockholm, Sweden), C. Treharne (London, United Kingdom), C. Mccrea (Cambridge, United Kingdom), S. Arnetorp (Mölndal, Sweden), E. de Nigris (Cambridge, United Kingdom), U. Holmgren (Mölndal, Sweden), P. Miller (Manchester, United Kingdom), P. Varghese (Gaithersburg, United States of America), J. Haughney (Glasgow, United Kingdom)
| |
Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD
G. Ferguson (Farmington Hills, MI, United States of America), C. Barnes (South San Francisco, CA, United States of America), G. Crater (South San Francisco, CA, United States of America)
| |
Effect of azithromycin treatment on inflammation in COPD patients
R. Lababidi (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), J. Simpson (Newcastle, Australia), M. Bafadhel (Oxford, United Kingdom)
| |
Carbocisteine in vivo reduces circulating miR-21 and IL-8 in exacerbated COPD patients
M. Ferraro (Pa, Italy), S. Di Vincenzo (Pa, Italy), S. Bucchieri (Pa, Italy), P. Dino (Pa, Italy), M. Leto Barone (Pa, Italy), S. Gangemi (Me, Italy), F. Saibene (Mi, Italy), L. Lanata (Mi, Italy), E. Pace (Pa, Italy)
| |
Application of erdosteine in the treatment of occupational chronic obstructive pulmonary disease
O. Boiko (Dnipro, Ukraine), V. Rodionova (Dnipro, Ukraine), K. Gashynova (Dnipro, Ukraine)
| |
Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B).
I. Khachatryan (Yerevan, Armenia), M. Narimanyan (Yerevan, Armenia)
| |
Late Breaking Abstract - Indacaterol/glycopyrronium versus salmeterol/fluticasone in chronic obstructive pulmonary disease: a meta-analysis on the protection against the risk of exacerbation
O. Bonavita (Origgio, Italy), V. Vinaccia (Origgio, Italy), P. Morini (Origgio, Italy)
| |
Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD
K. Takahashi (Saga, Japan), M. Uchida (Saga, Japan), G. Kato (Saga, Japan), A. Takamori (Saga, Japan), H. Sadamatsu (Saga, Japan), M. Tanaka (Saga, Japan), R. Tajiri (Saga, Japan), T. Kinoshita (Fukuoka, Japan), K. Kojima (Saga, Japan), M. Yoshida (Fukuoka, Japan), H. Tashiro (Saga, Japan), S. Hayashi (Fukuoka, Japan), A. Kawaguchi (Saga, Japan), N. Sueoka-Aragane (Saga, Japan), T. Kawayama (Fukuoka, Japan)
| |